Current and Future Clinical Cancer Advances

Clinical cancer advances in research are featured in this year’s 2021 ASCO report reflect progress in a range of cancers and across prevention and treatment.

Highlights in the Report Cancer Advances:

  • Molecular Profiling Drives Progress in GI Cancers.
  • Antibody-Drug Conjugate Shows Promise in GI Cancers.
  • Pembrolizumab Doubles Time to Disease Progression in Patients With Advanced Colorectal Cancer With DNA Mismatch Repair Deficiency.
  • Progress in bringing targeted therapies to patients with earlier-stage disease.
  • Biomarker-driven treatment approaches that offer more personalized care for lung, colorectal, and gastric cancers.
  • Combinations of different therapies that extend survival without increasing toxicity.
  • A growing number of targeted therapies are offering extended survival for more patients with difficult-to-treat cancers.

Current and Future Clinical Cancer Advances

Research Priorities in Clinical Cancer for 2021

  • Develop and Integrate Artificial Intelligence and Deep Learning in Cancer Research
  • Identify Strategies That Predict Response and Resistance to Immunotherapies
  • Optimize Multimodality Treatment for Solid Tumors
  • Increase Precision Medicine Research and Treatment Approaches in Pediatric and Other Rare Cancers
  • Optimize Care for Older Adults With Cancer
  • Increase Equitable Access to Cancer Clinical Trials
  • Reduce Adverse Consequences of Cancer Treatment
  • Reduce Obesity’s Impact on Cancer Incidence and Outcomes
  • Better Identify Potentially Malignant Lesions and Predict When Treatment is Needed

Problems in Clinical Cancer 2021

The COVID-19 public health emergency threatens to reverse years of momentum in cancer research. Laboratories conducting cancer research have closed or space has been redirected to COVID-19 research. Clinical trials and cancer advances have halted or slowed, creating a costly loss in research progress and delays in patient access to potentially life-saving treatments.


Leave a Reply